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Objective: Our objective was to evaluate the association of chronic kidney dysfunction in patients with multi-
vessel chronic coronary artery disease, preserved left ventricular function, and the possible interaction between
received treatment and cardiovascular events.
Methods: The glomerular filtration rate was determined at baseline on 611 patients who were randomized into
three treatment groups: medical treatment, percutaneous coronary intervention, and coronary artery bypass sur-
gery. Incidence of myocardial infarction, angina requiring a new revascularization procedure, and death were an-
alyzed during 5 years in each group.
Results: Of 611 patients, 112 (18%) were classified as having normal renal function, 349 (57%) were classified
as having mild dysfunction, and 150 (25%) were classified as having moderate dysfunction. There were signif-
icant differences among the cumulative overall mortality curves among the three renal function groups. Death was
observed more frequently in the moderate dysfunction group than the other two groups (P<.001). Interestingly,
in patients with mild chronic kidney dysfunction, we observed that coronary artery bypass treatment presented
a statistically higher percentage of event-free survival and lower percentage of mortality than did percutaneous
coronary intervention or medical treatment
Conclusions: Our results confirm that coronary artery disease accompanied by chronic kidney dysfunction has
a worse prognosis, regardless of the therapeutic strategy for coronary artery disease, when renal function is at least
mildly impaired. Additionally, our data suggest that the different treatment strategies available for stable coronary
artery disease may have differential beneficial effects according to the range of glomerular filtration rate strata.Chronic kidney disease (CKD) is strongly associated with
a higher risk of cardiovascular disease on presentation, and
the presence of CKD is a potent predictor of a worse prog-
nosis among patients with already established coronary ar-
tery disease (CAD).1-4 Studies have shown that at least
25% of the patients in dialysis had CAD,5-7 and 10% had
a previous myocardial infarction (MI).6 Adverse outcomes
occur more often in end-stage CKD, and a higher risk of
complications after revascularization procedures, percutane-
ous coronary intervention (PCI), or coronary artery bypass
grafting (CABG) is present in these patients.8,9 More re-
cently, even earlier stages of CKD have been associated
with worse outcomes in patients with CAD.10,11 However,
limited information exists regarding the interaction between
different treatment options for chronic CAD and mild renal
dysfunction.
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long-term clinical effect of medical treatment (MT) versus
PCI or CABG in patients with mild or moderate renal dys-
function who have multivessel disease. We, therefore, ex-
plored the effect of mild or moderate CKD on the clinical
outcomes of patients enrolled in the Medical, Angioplasty
or Surgery Study (MASS II), comparing the impact of the
three therapeutic option strategies in patients with symptom-
atic multivessel CAD stratified by CKD level.
METHODS
Study Design and Patients
This post hoc analysis used data from a previously conducted random-
ized trial and was approved by the Ethics Committee of the Heart Institute
of the University of Sa˜o Paulo Medical School. MASS II, a randomized trial
that evaluated the long-term relative efficacies of three possible therapeutic
strategies for patients with multivessel CAD, stable angina, and preserved
left ventricular function, was described previously.12 In brief, 611 patients
have given written, informed consent and were randomly assigned to MT
(n ¼ 203), PCI (n ¼ 205), or CABG (n ¼ 203) if there was agreement on
the part of the surgeon, attending physicians, and interventional cardiolo-
gists that revascularization could be attained by either strategy. All patients
had angiographicaly documented proximal multivessel coronary stenosis of
more than 70% by visual assessment and documented ischemia, defined by
either stress testing or typical stable angina assessment of the Canadian Car-
diovascular Society (class II or III).
Exclusion criteria included unstable angina or acute MI necessitating
emergency revascularization, ventricular aneurysm necessitating surgical
repair, left ventricular ejection fraction of less than 40%, a history of PCI
or CABG, single-vessel disease, or previous cardiac surgery. Patients
were also excluded if they were unable to understand or cooperate withrdiovascular Surgery c Volume 137, Number 6 1443




APPROACH ¼ Alberta Provincial Project for
Outcomes Assessment in Coronary
Heart Disease
CABG ¼ coronary artery bypass grafting
CAD ¼ coronary artery disease
CI ¼ confidence interval
CKD ¼ chronic kidney dysfunction
eGFR ¼ estimated glomerular filtration rate
HDL ¼ high-density lipoprotein
MASS II ¼ Medicine, Angioplasty, or
Surgery Study
MDRD ¼ Modification of Diet in
Renal Disease
MI ¼ myocardial infarction
MT ¼ medical treatment
NKF ¼ National Kidney Foundation
PCI ¼ percutaneous coronary intervention
PRESTO ¼ Results of Prevention of
REStenosis with Tranilast and
its Outcomes
RF ¼ renal function
RR ¼ relative risk
the protocol requirements or to return for follow-up. By original study de-
sign, patients with end-stage CKD were not included in this study.
Treatment Intervention
All patients were placed on an optimal regimen consisting of a stepped-
care approach using nitrates, aspirin, beta-blockers, calcium channel
blockers, angiotensin-converting enzyme inhibitors, or a combination of
these drugs, unless contraindicated. Lipid-lowering agents, particularly sta-
tins, were also prescribed, along with a low-fat diet, on an individual basis.
Patients were then randomized to continue with aggressive MT alone or to
undergo PCI or CABG concurrently with MT.
Requirements were to perform optimum coronary revascularization in
accordance with current best practices. Equivalent anatomic revasculariza-
tion was encouraged but not mandatory. For patients assigned to PCI, the
procedures were performed within 3 weeks after randomization. Multivessel
PCI was performed in 73% of the patients. Immediate angiographic success
was achieved in 92% of patients in whom it was attempted, and 72% of
them received at least one stent (62% received two or more stents). Com-
plete revascularization was achieved in 41% of patients treated. Glycopro-
tein IIb/IIIa agents were not used. For patients assigned to CABG, the
procedures were performed within 12 weeks after randomization. Complete
resvacularization was accomplished in 74% of the patients. At least one in-
ternal thoracic artery was used for grafting in 92% of the cases. No off-
pump CABG was performed.
Baseline Measurement of Renal Function
All patients obtained the last single serum creatinine immediately before
randomization. We estimated the glomerular filtration rate (eGFR) based on
the Modification of Diet in Renal Disease (MDRD) study equation, as sug-
gested by the National Kidney Foundation (NKF) guidelines.13 The MDRD
formula is as follows: eGFR (mL/min per 1.73 m2)¼ (1863 [Serum Crea-
tinine]1.154 [mg/dL] 3 age [in years]). The product of this equation was1444 The Journal of Thoracic and Cardiovascular Sumultiplied by a correction factor of 0.742 in women and 1.210 in African
Brazilian patients. Patients were categorized in normal renal function
(RF) and mild or moderate CKD groups depending on their eGFR ( 90,
90–60, and 59–30 mL/min per 1.73m2, respectively), based on the National
Kidney Foundation (NFK) classification.
Study Outcomes
Adverse and other clinical events were tracked from randomization. Pa-
tients were assessed with follow-up visits every 6 months for 5 years at the
Heart Institute, University of Sa˜o Paulo Medical School. Angina was con-
sidered refractory only when patients had been treated with full anti-ische-
mic therapies to their level of tolerance. MI was defined as the presence of
significant new Q waves in at least two electrocardiographic leads or symp-
toms compatible with MI associated with creatine kinase MB fraction con-
centrations that were more than 3 times the upper limit of the reference
range. Stroke was defined as the presence of neurologic clinical symptoms
compatible with an episode of cerebrovascular ischemia associated with
a computed tomographic image compatible with neurologic infarction.
The pre-defined primary end point for this study was the incidence of
any-cause mortality, MI, refractory angina requiring revascularization, or
stroke. All patients in the PCI group had routine planned angiograms at 6
months. These angiograms were not considered an end point–associated
event because they were done independently of symptoms. Therapeutic
PCI or CABG performed during an episode of unstable angina at any
time during follow-up was considered an end-point event and was applied
equally across all three arms of therapy.
Statistical Analyses
Continuous variables were estimated as the mean value  SD. Discrete
variables were expressed as counts and percent values. Baseline clinical and
demographic variables were compared across RF categories with the Krus-
kal–Wallis test followed by the Dunn test for multiple analyses for continuous
variables and c2 for categorical variables. The event-free survival time was de-
fined as the interval between random assignment of treatment and the occur-
rence of one of the primary end points or the latest follow-up visit. Event-
free survival was estimated by the Kaplan–Meier method, and differences
among groups were assessed by the log–rank test. eGRF was analyzed as
a continuous value for the prediction of primary end points in univariate anal-
yses. Potential independent predictors of outcome were identified by univariate
analyses for each RF group by Cox proportional hazard analyses. Then, mul-
tivariate Cox proportional hazard survival analyses were performed to assess
whether the associations of RF groups with all-cause mortality and combined
end points were independent of potential confounders. Results are described as
relative risks (RR; hazard ratio) with 95% confidence intervals (CI). All anal-
yses were based on the intention-to-treat principle, and statistical tests were 2
tailed. Statistical analysis was performed with the Statistical Analysis System
6.14 software (SAS Institute, Inc, Cary, NC).
RESULTS
Baseline Variables
In the study population of 611, 112 (18%) patients were
classified as having normal RF, 349 (57%) were classified
as having mild CKD, and 150 (25%) were classified as hav-
ing moderate CKD. Treatment assigned and baseline charac-
teristics were similar among RF groups, except by age,
smoking, body mass index, number of diseased vessels, try-
glicerides, and high-density lipoprotein (HDL) cholesterol
levels. The mild RF group more often were smokers, over-
weight, and had triple-vessel disease. On the other hand,
across worsening RF categories, patients were older and
more likely to have lower tryglicerides and higher HDLrgery c June 2009
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Normal renal
function (n ¼ 112)
Mild renal
dysfunction (n ¼ 349)
Moderate renal
dysfunction (n ¼ 150) P value
Male, n (%) 79 (70) 243 (69) 101 (67) .832
Hypertension, n (%) 47 (41) 124 (35) 57 (38) .969
Angina CCS II/III, n (%) 13 (11) 47 (13) 15 (10) .541
Diabetes, n (%) 66 (58) 219 (62) 90 (60) .711
Smoker, n (%) 64 (57) 229 (65) 111 (74) .016
2-vessel disease, n (%) 52 (46) 152 (43) 49 (32) .038
3-vessel disease, n (%) 60 (53) 197 (56) 101 (67) .038
MI, n (%) 67 (59) 187 (53) 87 (58) .422
Body mass index>25, n (%) 97 (86) 230 (65) 81 (54) .001
Age, median (years) 51 59 67 < .05
Triglycerides, mean  SD (mg/dL) 225  146 192  113 180  115 *
HDL cholesterol, mean  SD (mg/dL) 35  7 37  10 39  11 *
Treatment
PCI 40 (35) 116 (33) 49 (32)
CABG 35 (31) 122 (34) 46 (30) .792
MT 37 (33) 111 (31) 55 (36)
Percentages were calculated from a total number in a given renal function group. CCS, Canadian Cardiovascular Society; MI, myocardial infarction; HDL, high-density lipoprotein;
SD, standard deviation; PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting; MT, medical treatment. *P< .05 among three groups; after Dunn test,
P value< .05 of the variable remains significant only between moderate and normal.A
C
Dcholesterol levels (Table 1). We did not observe differences
in the prevalence of comorbidities such as hypertension or
diabetes mellitus across the range of RF categories. At study
entry, 33.4% were receiving angiotensin-converting en-
zyme inhibitor (Table 2).
The in-hospital mortality rates were 7.3%, 2.51%, and
1.33%, respectively, for the moderate CKD, mild CKD,
and normal RF groups (P ¼ .069). Concurrently, the com-
bined event incidence was 12.63%, 8.37%, and 12.00%, re-
spectively (P ¼ .413).
Five-Year Clinical Outcome
The vital status of all randomly assigned patients was ascer-
tained in May 2005. The minimal duration of follow-up was
5 years. No patient was lost to follow-up in all three groups.
Table 3 shows the clinical outcomes of RF groups after 5
years of follow-up. Death was observed more frequently in
the moderate CKD group than in the other groups (P<.001).
Event-Free Survival
Figure 1, A, shows the combined events, namely inci-
dence of overall mortality, MI, refractory angina necessitat-ing hospitalization, or stroke among the three RF groups
across 60 months. The rates of event-free survival were
significantly different among patients among the three
RF groups (P ¼ .0013), whereas the moderate CKD group
presented more combined events than did the mild CKD
or normal RF groups (60%, 40%, and 20%, respectively).
The pairwise RF group comparisons of the primary end
points demonstrated that patients with moderate CKD had
2.1-fold (95% CI, 1.309–3.293; P<.001) greater risk of
combined events than did those normal RF groups (refer-
ence group). On the other hand, no significant difference
was found on the risk of primary end points between normal
RF and mild RF (95% CI, 0.846–2.028; P ¼ .226).
Overall Mortality
There were significant differences among the cumulative
overall mortality curves among the three RF groups (Fig-
ure 1, B). The moderate CKD group had more deaths than
did the other two groups (P ¼ .0007). We observed that pa-
tients with moderate CKD had a 4.4-fold (95% CI, 1.71–
11.54; P ¼ .002) increased mortality risk compared with
the normal RF group (reference). The pairwise RF groupTABLE 2. Medication in use by renal function group
Normal renal function Mild renal dysfunction Moderate renal dysfunction P value
Beta-blocker, n (%) 90 (80) 281 (82) 121 (76) .279
Calcium blocker channel, n (%) 66 (59) 191 (56) 84 (53) .676
Antiplatelets, n (%) 110 (98) 325 (95) 151 (96) .388
Nitrates, n (%) 96 (85) 284 (83) 132 (83) .828
ACE inhibitor, n (%) 40 (35) 108 (31) 56 (35) .580
Statin, n (%) 83 (74) 209 (60) 87 (58) .056
Oral antidiabetic, n (%) 14 (12) 51 (15) 19 (12) .618
ACE, Angiotensin-converting enzyme.
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Normal renal function Mild renal dysfunction Moderate renal dysfunction P value
New CABG, n (%) 12 (10) 26 (7) 13 (8) .547
New PCI, n (%) 11 (9) 40 (11) 19 (12) .774
MI, n (%) 8 (7) 22 (6) 15 (10) .348
Stroke, n (%) 4 (3) 11 (3) 11 (7) .097
Death, n (%) 5 (4) 33 (9) 27 (18) .001
CABG, coronary artery bypass grafting; PCI, percutaneous coronary intervention; MI, myocardial infarction.comparisons of mortality demonstrate no difference between
normal RF versus mild RF (95% CI, 0.84–5.57; P ¼ .105).
CAD Treatment and CKD
When we stratified each RF groups based on the CAD
treatment, we did not observe significant differences among
the three therapeutic strategies regarding the percentage of
event-free survival and mortality in moderate or normal
RF groups at 5 years of follow-up (Figure 2).
Interestingly, in CKD patients with mild dysfunction, we
observed that CABG treatment presented a statistically
higher event-free survival and lower mortality rate than
did PCI or MT (Figure 2, C and D). Treatment and age
were the predictors of worse combined events in those pa-
tients (P< .0001 and P ¼ .0229, respectively). However,
the received treatment was the only predictor for mortality
(P< .01). By using a multivariate logistic regression model
and a Cox proportional hazards risk, adjusted for age, sex,
body mass index, smoking status, hypertension, MI, total
cholesterol, HDL cholesterol, triglycerides, ejection frac-
tion, diabetes, angina status, number of diseased vessels,
and treatment allocation, a significant protective effect is
observed for CABG compared with MT and PCI treatment
in the mild CKD group. The risk of combined events
increased 2.9-fold (95% CI, 1.68–5.07; P < .001) and
2.8-fold (95%CI, 1.63–4.94; P<.001) in patients subjected
to MT and PCI, respectively, compared with CABG treat-
ment. Additionally, the risk of death was higher in MT
patients compared with the CABG group (RR ¼.35; 95%
CI, 1.22–9.23; P ¼ .019), but no difference between
PCI-treated patients compared with the CABG group
(RR ¼ 2.7; 95% CI, 0.97–7.66; P ¼ .056) was observed.
DISCUSSION
Our results confirm that CAD accompanied by CKD has
a worse prognosis, regardless of the therapeutic strategy for
CAD, when RF is at least mildly impaired. The lowest eGFR
group had a 4.5-fold increased risk of death within 5 years
compared with the normal eGFR group. Additionally, our
data suggest that the different treatment strategies available
for stable CAD may have differential beneficial effects
according to the range of eGFR strata. We showed that
patients with stable multivessel CAD and CKD, mainly in
early stages, had more events when kept in MT over 5 years1446 The Journal of Thoracic and Cardiovascular Suof follow-up. Of note, CABG patients compared with the
PCI or MT patients had a better free-event survival curve
and less overall mortality rates only in patients with mild
CKD (or stage 2 CKD). However, among patients with mod-
erate CKD, CABG surgery did not convey a survival benefit
over PCI or MT.
Prior studies in high-risk populations, such as those who
already have CAD or who have many risk factors for cardio-
vascular disease, have suggested that the level of kidney
function is a risk factor for cardiovascular disease out-
comes.14-18 Our results add to a growing body of literature
documenting the effects of mild to moderate renal disease
on outcomes in patients with CAD.1,19
FIGURE 1. A, Kaplan–Meier curves for combined events, namely inci-
dence of overall mortality, myocardial infarction, refractory angina requir-
ing hospitalization, or stroke according to three renal function groups across
60 months. B, Kaplan–Meier curves for overall mortality incidence among
the three renal function groups across 60 months. CKD, Chronic kidney
disease.rgery c June 2009
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DFIGURE 2. Kaplan–Meier curves depicting the incidence of combined end points (A, C, and E) and overall mortality (B, D, and F) according to estimated
glomerular filtration rate strata: normal (A, B), mild dysfunction (C, D), and moderate dysfunction (E, F), after 60 months’ follow-up. CKD, Chronic kidney
disease; CABG, coronary artery bypass graft; MT, medical therapy; PCI, percutaneous coronary intervention.Our data are consistent with the results of most, but not all,
previous studies on the association between minor renal im-
pairment and cardiovascular outcomes.1-5 Some of these dis-
crepancies might be limited by insufficient adjustment for
traditional risk factors or clinical differences on CAD pre-
sentation, use of serum creatinine as the measure of kidney
function, and different cutoff points for CKD definition.
Indeed, the mortality and risk of cardiovascular events ap-
pears to be directly proportional to decreasing GFR esti-
mates. We could observe in-hospital mortality nearly 6
and 2 times greater in the moderate and mild impairment
RF groups, respectively, than the normal RF group. Con-
versely, the mortality rate at 5 years’ follow-up was nearly
5 and 2 times higher for moderate and mild CKD, respec-
tively, than the normal RF group. Moderate CKD is ad-
versely associated with 5-year cardiovascular outcomes inThe Journal of Thoracic and Capatients with multivessel disease, regardless of the therapeu-
tic strategy applied. In our model, moderate CKD (4.4-fold
and 2.1-fold increased risk, respectively) and older age
(2.5-fold and 1.7-fold increased risk, respectively) were
strong and independent predictors of mortality and event-
free survival at 5 years.
Additionaly, we found that patients with moderate dys-
function were older in our study. However, when we ana-
lyzed just the group with moderate CKD, we could not
observe any known risk factor as a predictor of the worse
outcome and higher mortality seen in this group; the studies
of others reported that CKD patients have increased age, di-
abetes, and prevalence of hypertension compared with those
with normal RF.2,15
In CKD patients, the optimal approach to revasculariza-
tion has not been determined. Previous reports demonstratedrdiovascular Surgery c Volume 137, Number 6 1447
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over MT alone or percutaneous revascularization with non-
drug–eluting stents.7,20-22 Regarding PCI treatment, mild
CKD is associated with lower procedural success and in-
creased in-hospital complications after PCI.22,23 Even if
the PCI procedure is successful, cardiovascular events and
mortality are increased up to 50% compared with patients
having normal renal function.22 Those studies have been
limited, however, by the inability to adjust clinical variables,
such as severity of CAD and left ventricular dysfunction and
other comorbid factors.
More recently, the Results of Prevention of REStenosis
with Tranilast and its Outcomes (PRESTO) trial demon-
strated an improvement in the results of stent implantation
in patients even with renal dysfunction.23 They suggested
that the results of PCI in CKD are now comparable with re-
sults in the general population and that the subsequently in-
creased mortality is not a result of procedural complications
or restenosis in the CKD patients, but because of the higher
burden of cardiovascular and other comorbid diseases in this
particular subpopulation.
In the literature, few studies address the comparison of the
three therapeutic strategies to CAD and CKD. The Alberta
Provincial Project for Outcomes Assessment in Coronary
Heart Disease (APPROACH),24 an observational cohort
study that compared survival by treatment group (PCI,
MT, and CABG) for patients with three categories of RF (di-
alysis-dependent, non-dialysis dependent, and a reference
group with serum creatinine less than 2.3 mg/dL). In this
study, an advantage of an interventionist approach over
MT was observed, with noticeable reduction on mortality.
The Duke Databank for Cardiovascular Diseases analyzed
retrospectively 4584 patients with documented stenosis
greater than 75% of at least one coronary artery. CKD
was staged using creatinine clearance derived from the
Cockcroft–Gault formula.25 They observed that either PCI
or CABG was superior to MT in patients with CKD, and
in patients with CKD, mainly severe, CABG was associated
with greater mortality reduction than PCI. Although similar
to our RF classification, the study design, no randomization,
and the different overall number of diseased vessels could
potentially lead to different results from the ones provided
by our work.
Different from what occurred in the previous studies,
mortality was significantly reduced only in patients with
mild CKD who underwent CABG compared with MT in
our work. After multivariate regression adjustment, we evi-
denced 2.9-fold and 2.8-fold increased risk of events and
3.4-fold and 2.7-fold increased risk of death in MT and
PCI compared with CABG, respectively, and no difference
between PCI and MT. It shows the advantage of CABG
over the other two forms of therapy in the early stages of
CKD. Still, PCI failed to show an advantage over MT re-
garding the number of deaths.1448 The Journal of Thoracic and Cardiovascular SuThe major new finding of our study is that in a randomized
selected population comparing the three current therapeutic
strategies for multivessel stable CAD, the presence of mild
CKD, which was observed in 53% of the patients, modu-
lates in this rather specific group a differential treatment ef-
fect on long-term survival and event rates. Surprisingly, the
superiority of CABG over either PCI or MT observed in
mild CKD was not observed in patients with moderate
CKD, in whom a worse prognosis was evident for all three
treatment groups.
Interestingly, the mild RF group more closely resembled
the moderate RF group than the normal RF group. This dem-
onstrates that discrete variations in renal kinetics can lead to
systemic repercussions. Assessment of reinterventional pro-
cedures showed that patients with mild CKD and initially
randomized to MT had more new CABG procedures and
that those randomized to PCI had more new PCI procedures.
This suggests that MT should not be encouraged for this
group of CKD patients.
Understanding the impact of mild CKD on prognosis and
therapeutic strategies of stable multivessel CAD is important,
because mild CKD is more than 10 times more prevalent than
the end-stage CKD and affects approximately 11% of the
population.5 Thus, these findings highlight the clinical impor-
tance of mild CKD in the decision-making process of the best
therapeutic option for patients with stable multivessel CAD.
In conclusion, renal dysfunction is common in the popu-
lation with stable multivessel CAD and carries an important
predictive role in terms of differential treatment effect on
outcomes. A survival and event-free benefit among patients
with mild CKD undergoing CABG over PCI or MT was ob-
served. In addition, moderate loss of RF is strongly associ-
ated with an increased risk of worse prognosis in CAD,
regardless of the therapeutic strategy.
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